Abstract
p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Current Cancer Drug Targets
Title: p53: Fighting Cancer
Volume: 4 Issue: 5
Author(s): Galina Selivanova
Affiliation:
Keywords: p53, apoptosis, mitochondrial, anti-cancer strategies, hypoxia
Abstract: p53 is a key tumor suppressor that plays a critical role in coordinating the response of cells to a diverse range of stress conditions, e.g. oncogenic activation, hypoxia or DNA damage. Induction of cell death by apoptosis in response to stress by p53 is crucial for the prevention of tumor development as well as for the response to anticancer therapy. p53 triggers apoptosis through multiple mechanisms, including mitochondrial and death receptor pathways, cytoskeleton changes, suppression of survival signalling, and induction of hypoxia. Lesions in the p53 pathway occur so frequently in cancer, regardless of patient age or tumor type, that they appear to be part of the life history of a majority of cancer cells. Given an extremely high potency of apoptosis induction by functional p53, it appears that anti-cancer strategies based on p53 reactivation should be efficient and applicable in a wide range of human tumors. Tumor cells are prone to p53-induced apoptosis due to oncogene activation. Therefore it is conceivable that p53-based therapeutic strategies will not require selective targeting of tumor cells.
Export Options
About this article
Cite this article as:
Selivanova Galina, p53: Fighting Cancer, Current Cancer Drug Targets 2004; 4 (5) . https://dx.doi.org/10.2174/1568009043332934
DOI https://dx.doi.org/10.2174/1568009043332934 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry Targeting Platinum Resistant Disease in Ovarian Cancer
Current Medicinal Chemistry Effect of Environmental Substances on the Activity of Arylamine N-Acetyltransferases
Current Drug Metabolism rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine
Current Topics in Medicinal Chemistry Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Intravesical Chemotherapy and Chemohyperthermia in Non-Muscle-Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics
Current Drug Metabolism Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design SAGE Application in the Study of Diabetes
Current Pharmaceutical Biotechnology Cytochrome P450 Gene Polymorphism and Cancer
Current Drug Metabolism Pharmacotherapy for the Metabolic Syndrome
Current Vascular Pharmacology A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry The Re-Emergence of Aerosol Gene Delivery: A Viable Approach to Lung Cancer Therapy
Current Cancer Drug Targets